Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis.
Audrey PayancéGilberto Silva-JuniorJulien BissonnetteMarion TanguyBlandine PasquetCristina LeviOlivier RouxOuardia NekachtaliAnna BaigesVirginia Hernández-GeaCédric LaouénanDidier LebrecMiguel AlbuquerqueValérie ParadisRichard MoreauDominique VallaFrançois DurandChantal M BoulangerJuan-Carlos Garcia-PaganPierre-Emmanuel RautouPublished in: Hepatology (Baltimore, Md.) (2018)
Circulating MV levels cannot identify patients with HVPG ≥10 mm Hg; by contrast, hepatocyte MV levels strongly improve prediction of 6-month mortality in patients with advanced chronic liver disease; therapies associated with decreased levels of circulating hepatocyte MV might be attractive strategies in patients with severe cirrhosis. (Hepatology 2018).